AMAG Pharmaceuticals (NASDAQ:AMAG) : Traders are bullish on AMAG Pharmaceuticals (NASDAQ:AMAG) as it has outperformed the S&P 500 by a wide margin of 17.82% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.1%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 2.4% in the last 1 week, and is up 19.72% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have dropped -64.91% from its 1 Year high price. On Jul 17, 2015, the shares registered one year high at $77.73 and the one year low was seen on May 19, 2016. The 50-Day Moving Average price is $22.56 and the 200 Day Moving Average price is recorded at $23.72.
The stock has recorded a 20-day Moving Average of 7.18% and the 50-Day Moving Average is 14.5%.
AMAG Pharmaceuticals (NASDAQ:AMAG): On Fridays trading session , Opening price of the stock was $25.56 with an intraday high of $25.87. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $24.51. However, the stock managed to close at $25.19, a loss of 0.71% for the day. On the previous day, the stock had closed at $25.37. The total traded volume of the day was 796,034 shares.
In an insider trading activity, The Securities and Exchange Commission has divulged in a Form 4 filing that the director of Amag Pharmaceuticals Inc., Fallon John A. had purchased shares worth of $100,776 in a transaction dated on November 10, 2015. A total of 3,230 shares were purchased at a price of $31.2 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on maternal health, anemia and cancer supportive care. The Company markets Makena (hydroxyprogesterone caproate injection), Feraheme (ferumoxytol) Injection for Intravenous (IV) use and MuGard Mucoadhesive Oral Wound Rinse. Feraheme is an IV iron replacement therapy for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD). Feraheme is approved for marketing in the United States. Makena is a drug indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. MuGard is indicated for the management of oral mucositis/stomatitis and all types of oral wounds, including aphthous ulcers/canker sores and traumatic ulcers, such as those caused by oral surgery or ill-fitting dentures or braces.